Lantern Pharma Inc. (NASDAQ: LTRN) Reports Q2 Results with Clinical Trial, AI Platform Advancements
Lantern Pharma completed enrollment in its LP-184 Phase 1a trial and is preparing Phase 1b/2 studies in cancers with large market potential. Early patient responses across LP-184, LP-284, and LP-300 trials highlight clinical activity in difficult-to-treat cancers. Intellectual property expanded with new European patent allowance for LP-284 and publication of blood-brain barrier prediction patent. Enhancements to RADR(R), the company’s AI platform, include public launch of…